株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

視神経脊髄炎関連疾患(NMOSD)- 市場洞察、疫学、市場予測 2028年

Neuromyelitis optica spectrum disorder (NMOSD) - Market Insights, Epidemiology and Market Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 736661
出版日 ページ情報 英文 162 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.55円で換算しております。
Back to Top
視神経脊髄炎関連疾患(NMOSD)- 市場洞察、疫学、市場予測 2028年 Neuromyelitis optica spectrum disorder (NMOSD) - Market Insights, Epidemiology and Market Forecast-2028
出版日: 2019年07月01日 ページ情報: 英文 162 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の視神経脊髄炎関連疾患(NMOSD)の有病数は2017年に2万2,648万米ドル、その市場規模は2億3,640万米ドルと推計されています。

当レポートでは、主要7カ国の世界の視神経脊髄炎関連疾患(NMOSD)市場を調査し、疾病の概要や現行の治療法、新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 主要洞察

第2章 視神経脊髄炎関連疾患(NMOSD)市場:概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • 兆候と症状
  • 視神経脊髄炎(NMO)/視神経脊髄炎関連疾患(NMOSD)の臨床的特徴
  • 分類
  • 病因
  • 診断
  • 国際コンセンサス診断基準
  • 神経イメージングと神経生理学的テスト
    • AQP4-IgG血清学的検査およびその他の臨床検査に関する考慮事項
    • 小児性NMOSDの基準
    • 単相性NMOSD
    • NMOSDに関連する全身性自己免疫
    • 病理
    • 視神経脊髄型多発性硬化症(OSMS)

第4章 疫学および患者人口

  • 主な調査結果

第5章 主要7カ国のNMO/NMOSDの有病数

第6章 国別の疫学

  • 米国
    • 仮定と理論的根拠
    • NMO/NMOSDの総有病数
    • NMO/NMOSDの総有病数:性別
    • NMO/NMOSDの総診断数
    • NMO-IgGの診断数
    • NMO/NMOSDの臨床的特徴
    • NMO/NMOSDのイベント
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • スペイン
  • 日本

第7章 治療法

  • 治療アルゴリズム
    • 急性発作の治療
    • 再発に対する予防的治療
  • 国別の治療ガイドライン

第8章 アンメットニーズ

第9章 キークロスコンペティター

第10章 新薬

  • INEBILIZUMAB:VIELA BIO
    • 医薬品概要
    • その他の開発活動
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • SATRALIZUMAB(SA237):中外製薬/Roche
  • SOLIRIS:ALEXION PHARMA
    • 規制のマイルストーン
  • ULTOMIRIS:ALEXION

第11章 視神経脊髄炎(NMO):主要7カ国の市場分析

  • 主な調査結果
  • 主要7カ国のNMO/NMOSDの市場規模

第12章 米国市場の見通し

  • NMO/NMOSDの総市場規模
  • NMO急性期管理の市場規模:治療薬別
  • NMO予防的管理の市場規模:治療薬別
  • 新薬の市場規模

第13章 EU5カ国市場の見通し

  • ドイツ
    • NMO/NMOSDの総市場規模
    • NMO急性期管理の市場規模:治療薬別
    • NMO予防的管理の市場規模:治療薬別
    • 新薬の市場規模
  • フランス
  • イタリア
  • 英国
  • スペイン

第14章 日本市場の見通し

  • NMO/NMOSDの総市場規模
  • NMO急性期管理の市場規模:治療薬別
  • NMO予防的管理の市場規模:治療薬別
  • 新薬の市場規模

第15章 市場の成長要因

第16章 市場の障壁

第17章 付録

  • 調査手法

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1: Signs and Symptoms of Neuromyelitis Optica
  • Table 2: Brain symptoms in Neuromyelitis Optica
  • Table 3: NMOSD diagnostic criteria for adult patients
  • Table 4: Red flags: Findings atypical for NMOSD
  • Table 5: Neuroimaging characteristics of NMOSD
  • Table 6: Total Prevalent Population of NMO/NMOSD in the 7MM (2017-2028)
  • Table 7: Total Prevalent Population of NMO/NMOSD in the US (2017-2028)
  • Table 8: Gender Specific Prevalence of NMO/NMOSD in the US (2017-2028)
  • Table 9: Diagnosed Cases of Neuromyelitis Optica in the US (2017-2028)
  • Table 10: NMO-IgG Diagnosed Cases of NMO/NMOSD in the US (2017-2028)
  • Table 11: Clinical Characterization of NMO/NMOSD in the US (2017-2028)
  • Table 12: Events of NMO/NMOSD in the US (2017-2028)
  • Table 13: Total Prevalent Population of NMO/NMOSD in Germany (2017-2028)
  • Table 14: Gender Specific Prevalence of NMO/NMOSD in Germany (2017-2028)
  • Table 15: Diagnosed Cases of Neuromyelitis Optica in Germany (2017-2028)
  • Table 16: NMO-IgG Diagnosed Cases of NMO/NMOSD in Germany (2017-2028)
  • Table 17: Clinical Characterization of NMO/NMOSD in Germany (2017-2028)
  • Table 18: Events of NMO/NMOSD in Germany (2017-2028)
  • Table 19: Total Prevalent Population of NMO/NMOSD in France (2017-2028)
  • Table 20: Gender Specific Prevalence of NMO/NMOSD in France (2017-2028)
  • Table 21: Diagnosed Cases of Neuromyelitis Optica in France (2017-2028)
  • Table 22: NMO-IgG Diagnosed Cases of NMO/NMOSD in France (2017-2028)
  • Table 23: Clinical Characterization of NMO/NMOSD in France (2017-2028)
  • Table 24: Events of NMO/NMOSD in France (2017-2028)
  • Table 25: Total Prevalent Population of NMO/NMOSD in Italy (2017-2028)
  • Table 26: Gender Specific Prevalence of NMO/NMOSD in Italy (2017-2028)
  • Table 27: Diagnosed Cases of Neuromyelitis Optica in Italy (2017-2028)
  • Table 28: NMO-IgG Diagnosed Cases of NMO/NMOSD in Italy (2017-2028)
  • Table 29: Clinical Characterization of NMO/NMOSD in Italy (2017-2028)
  • Table 30: Events of NMO/NMOSD in Italy (2017-2028)
  • Table 31: Total Prevalent Population of NMO/NMOSD in The UK (2017-2028)
  • Table 32: Gender Specific Prevalence of NMO/NMOSD in The UK (2017-2028)
  • Table 33: Diagnosed Cases of Neuromyelitis Optica in The UK (2017-2028)
  • Table 34: NMO-IgG Diagnosed Cases of NMO/NMOSD in the UK (2017-2028)
  • Table 35: Clinical Characterization of NMO/NMOSD in The UK (2017-2028)
  • Table 36: Events of NMO/NMOSD in The UK (2017-2028)
  • Table 37: Total Prevalent Population of NMO/NMOSD in Spain (2017-2028)
  • Table 38: Gender Specific Prevalence of NMO/NMOSD in Spain (2017-2028)
  • Table 39: Diagnosed Cases of Neuromyelitis Optica in Spain (2017-2028)
  • Table 40: NMO-IgG Diagnosed Cases of NMO/NMOSD in Spain (2017-2028)
  • Table 41: Clinical Characterization of NMO/NMOSD in Spain (2017-2028)
  • Table 42: Events of NMO/NMOSD in Spain (2017-2028)
  • Table 43: Total Prevalent Population of NMO/NMOSD in Japan (2017-2028)
  • Table 44: Gender Specific Prevalence of NMO/NMOSD in Japan (2017-2028)
  • Table 45: Diagnosed Cases of Neuromyelitis Optica in Japan (2017-2028)
  • Table 46: NMO-IgG Diagnosed Cases of NMO/NMOSD in Japan (2017-2028)
  • Table 47: Clinical Characterization of NMO/NMOSD in Japan (2017-2028)
  • Table 48: Events of NMO/NMOSD in Japan (2017-2028)
  • Table 49: Grading Recommendations for Neuromyelitis Optica
  • Table 50: Summary of treatments and recommendation levels used for Neuromyelitis Optica
  • Table 51: Inebilizumab, Clinical Trial Description, 2019
  • Table 52: Satralizumab, Clinical Trial Description, 2019
  • Table 53: Eculizumab, Clinical Trial Description, 2019
  • Table 54: 7 Major Market Size of NMO/NMOSD in USD Million (2017-2028)
  • Table 55: Market Size of NMO/NMOSD in the US, USD Million (2017-2028)
  • Table 56: Market Size by Therapies for Acute Management of NMO in the US, USD Million (2017-2028)
  • Table 57: Market Size by Therapies for Preventive Management of NMO in the US, in USD Million (2017-2028)
  • Table 58: Market Size by Emerging Therapies in the US, in USD Million (2017-2028)
  • Table 59: Market Size of NMO/NMOSD in Germany, USD Million (2017-2028)
  • Table 60: Market Size by Therapies for Acute Management of NMO in Germany, USD Million (2017-2028)
  • Table 61: Market Size by Therapies for Preventive Management of NMO in Germany, in USD Million (2017-2028)
  • Table 62: Market Size by Emerging Therapies in Germany, in USD Million (2017-2028)
  • Table 63: Market Size of NMO/NMOSD in France, USD Million (2017-2028)
  • Table 64: Market Size by Therapies for Acute Management of NMO in France, USD Million (2017-2028)
  • Table 65: Market Size by Therapies for Preventive Management of NMO in France, in USD Million (2017-2028)
  • Table 66: Market Size by Emerging Therapies in France, in USD Million (2017-2028)
  • Table 67: Market Size of NMO/NMOSD in Italy, USD Million (2017-2028)
  • Table 68: Market Size by Therapies for Acute Management of NMO in Italy, USD Million (2017-2028)
  • Table 69: Market Size by Therapies for Preventive Management of NMO in Italy, in USD Million (2017-2028)
  • Table 70: Market Size by Emerging Therapies in Italy, in USD Million (2017-2028)
  • Table 71: Market Size of NMO/NMOSD in the UK, USD Million (2017-2028)
  • Table 72: Market Size by Therapies for Acute Management of NMO in the UK, USD Million (2017-2028)
  • Table 73: Market Size by Therapies for Preventive Management of NMO in the UK, in USD Million (2017-2028)
  • Table 74: Market Size by Emerging Therapies in the UK, in USD Million (2017-2028)
  • Table 75: Market Size of NMO/NMOSD in Spain, USD Million (2017-2028)
  • Table 76: Market Size by Therapies for Acute Management of NMO in Spain, USD Million (2017-2028)
  • Table 77: Market Size by Therapies for Preventive Management of NMO in Spain, in USD Million (2017-2028)
  • Table 78: Market Size by Emerging Therapies in Spain, in USD Million (2017-2028)
  • Table 79: Market Size of NMO/NMOSD in Japan, USD Million (2017-2028)
  • Table 80: Market Size by Therapies for Acute Management of NMO in Japan, USD Million (2017-2028)
  • Table 81: Market Size by Therapies for Preventive Management of NMO in Japan, in USD Million (2017-2028)
  • Table 82: Market Size by Emerging Therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: Signs and symptoms of NMO/NMOSD
  • Figure 2: Clinical features of NMO/NMOSD
  • Figure 3: Neuromyelitis Optica Pathogenesis
  • Figure 4: Total Prevalent Patient Population of NMO/NMOSD in the 7MM (2017-2028)
  • Figure 5: Total Prevalent Population of NMO/NMOSD in the US (2017-2028)
  • Figure 6: Gender Specific Prevalence of NMO/NMOSD in the US (2017-2028)
  • Figure 7: Diagnosed Cases of NMO/NMOSD in the US (2017-2028)
  • Figure 8: NMO-IgG Diagnosed Cases of NMO/NMOSD in the US (2017-2028)
  • Figure 9: Clinical Characterization of NMO/NMOSD in the US (2017-2028)
  • Figure 10: Events of NMO/NMOSD in the US (2017-2028)
  • Figure 11: Total Prevalent Population of NMO/NMOSD in Germany (2017-2028)
  • Figure 12: Gender Specific Prevalence of NMO/NMOSD in Germany (2017-2028)
  • Figure 13: Diagnosed Cases of NMO/NMOSD in Germany (2017-2028)
  • Figure 14: NMO-IgG Diagnosed Cases of NMO/NMOSD in Germany (2017-2028)
  • Figure 15: Clinical Characterization of NMO/NMOSD in Germany (2017-2028)
  • Figure 16: Events of NMO/NMOSD in Germany (2017-2028)
  • Figure 17: Total Prevalent Population of NMO/NMOSD in France (2017-2028)
  • Figure 18: Gender Specific Prevalence of NMO/NMOSD in France (2017-2028)
  • Figure 19: Diagnosed Cases of NMO/NMOSD in France (2017-2028)
  • Figure 20: NMO-IgG Diagnosed Cases of NMO/NMOSD in France (2017-2028)
  • Figure 21: Clinical Characterization of NMO/NMOSD in France (2017-2028)
  • Figure 22: Events of NMO/NMOSD in France (2017-2028)
  • Figure 23: Total Prevalent Population of NMO/NMOSD in Italy (2017-2028)
  • Figure 24: Gender Specific Prevalence of NMO/NMOSD in Italy (2017-2028)
  • Figure 25: Diagnosed Cases of NMO/NMOSD in Italy (2017-2028)
  • Figure 26: NMO-IgG Diagnosed Cases of NMO/NMOSD in Italy (2017-2028)
  • Figure 27: Clinical Characterization of NMO/NMOSD in Italy (2017-2028)
  • Figure 28: Events of NMO/NMOSD in Italy (2017-2028)
  • Figure 29: Total Prevalent Population of NMO/NMOSD in The UK (2017-2028)
  • Figure 30: Gender Specific Prevalence of NMO/NMOSD in The UK (2017-2028)
  • Figure 31: Diagnosed Cases of NMO/NMOSD in The UK (2017-2028)
  • Figure 32: NMO-IgG Diagnosed Cases of NMO/NMOSD in the UK (2017-2028)
  • Figure 33: Clinical Characterization of NMO/NMOSD in The UK (2017-2028)
  • Figure 34: Events of NMO/NMOSD in The UK (2017-2028)
  • Figure 35: Total Prevalent Population of NMO/NMOSD in Spain (2017-2028)
  • Figure 36: Gender Specific Prevalence of NMO/NMOSD in Spain (2017-2028)
  • Figure 37: Diagnosed Cases of NMO/NMOSD in Spain (2017-2028)
  • Figure 38: NMO-IgG Diagnosed Cases of NMO/NMOSD in Spain (2017-2028)
  • Figure 39: Clinical Characterization of NMO/NMOSD in Spain (2017-2028)
  • Figure 40: Events of NMO/NMOSD in Spain (2017-2028)
  • Figure 41: Total Prevalent Population of NMO/NMOSD in Japan (2017-2028)
  • Figure 42: Gender Specific Prevalence of NMO/NMOSD in Japan (2017-2028)
  • Figure 43: Diagnosed Cases of NMO/NMOSD in Japan (2017-2028)
  • Figure 44: NMO-IgG Diagnosed Cases of NMO/NMOSD in Japan (2017-2028)
  • Figure 45: Clinical Characterization of NMO/NMOSD in Japan (2017-2028)
  • Figure 46: Events of NMO/NMOSD in Japan (2017-2028)
  • Figure 47: Treatment Algorithm of Neuromyelitis Optica
  • Figure 48: Unmet Needs of Neuromyelitis Optica
  • Figure 49: 7 Major Market Size of NMO/NMOSD in USD Million (2017-2028)
  • Figure 50: Market Size of NMO/NMOSD in the US, USD Million (2017-2028)
  • Figure 51: Market Size by Therapies for Acute Management of NMO in the US, USD Million (2017-2028)
  • Figure 52: Market Size by Therapies for Preventive Management of NMO in the US, in USD Million (2017-2028)
  • Figure 53: Market Size by Emerging Therapies in the US, in USD Million (2017-2028)
  • Figure 54: Market Size of NMO/NMOSD in Germany, USD Million (2017-2028)
  • Figure 55: Market Size by Therapies for Acute Management of NMO in Germany, USD Million (2017-2028)
  • Figure 56: Market Size by Therapies for Preventive Management of NMO in Germany, in USD Million (2017-2028)
  • Figure 57: Market Size by Emerging Therapies in Germany, in USD Million (2017-2028)
  • Figure 58: Market Size of NMO/NMOSD in France, USD Million (2017-2028)
  • Figure 59: Market Size by Therapies for Acute Management of NMO in France, USD Million (2017-2028)
  • Figure 60: Market Size by Therapies for Preventive Management of NMO in France, in USD Million (2017-2028)
  • Figure 61: Market Size by Emerging Therapies in France, in USD Million (2017-2028)
  • Figure 62: Market Size of NMO/NMOSD in Italy, USD Million (2017-2028)
  • Figure 63: Market Size by Therapies for Acute Management of NMO in Italy, USD Million (2017-2028)
  • Figure 64: Market Size by Therapies for Preventive Management of NMO in Italy, in USD Million (2017-2028)
  • Figure 65: Market Size by Emerging Therapies in the Italy, in USD Million (2017-2028)
  • Figure 66: Market Size of NMO/NMOSD in the UK, USD Million (2017-2028)
  • Figure 67: Market Size by Therapies for Acute Management of NMO in the UK, USD Millions (2017-2028)
  • Figure 68: Market Size by Therapies for Preventive Management of NMO in the UK, in USD Million (2017-2028)
  • Figure 69: Market Size by Emerging Therapies in the UK, in USD Million (2017-2028)
  • Figure 70: Market Size of NMO/NMOSD in Spain, USD Million (2017-2028)
  • Figure 71: Market Size by Therapies for Acute Management of NMO in Spain, USD Million (2017-2028)
  • Figure 72: Market Size by Therapies for Preventive Management of NMO in Spain, in USD Million (2017-2028)
  • Figure 73: Market Size by Emerging Therapies in Spain, in USD Million (2017-2028)
  • Figure 74: Market Size of NMO/NMOSD in Japan, USD Million (2017-2028)
  • Figure 75: Market Size by Therapies for Acute Management of NMO in Japan, USD Million (2017-2028)
  • Figure 76: Market Size by Therapies for Preventive Management of NMO in Japan, in USD Million (2017-2028)
  • Figure 77: Market Size by Emerging Therapies in Japan, in USD Million (2017-2028)
  • Figure 78: Market Drivers
  • Figure 79: Market Barriers
目次
Product Code: DIMI0373

DelveInsight's 'Neuromyelitis optica spectrum disorder (NMOSD) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NMOSD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Neuromyelitis optica spectrum disorder from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Neuromyelitis optica spectrum disorder (NMOSD) - Disease Understanding and Treatment Algorithm

The DelveInsight Neuromyelitis optica spectrum disorder market report gives the thorough understanding of the Neuromyelitis optica spectrum disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuromyelitis optica spectrum disorder in the US, Europe, and Japan.

Neuromyelitis optica spectrum disorder Epidemiology

The Neuromyelitis optica spectrum disorder (NMOSD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, gender-specific prevalent cases, diagnosed cases, NMO-IgG diagnosed cases, clinical characterization and events) scenario of Neuromyelitis optica spectrum disorder (NMOSD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, total prevalent population of Neuromyelitis optica spectrum disorder (NMOSD) in 7 major markets was found to be 22,648 in 2017. 

Neuromyelitis optica spectrum disorder Drug Chapters

This segment of the Neuromyelitis optica spectrum disorder report encloses the detailed analysis of Treatment Algorithm, Current Treatment, and Medical Practices Treatment of Neuromyelitis optica spectrum disorder aim at the management of acute attacks and the prevention of future exacerbations. Corticosteroids, plasma exchange, pain management, and physical or occupational therapy is used for treating Neuromyelitis Optica Spectrum Disorder. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The primary aspects of the treatment of Neuromyelitis Optica Spectrum Disorder focuses on the Treatment of attack, Prevention of attack, Treatment of residual symptoms of the relapse, Rehabilitation. At present, therapeutic classes of drugs contributing towards the market size of NMOSD includes, Intravenous Steroids like methyl-prednisolone, Plasma exchange, Intravenous cyclophosphamide, Intravenous immunoglobulin (IVIg) therapy, Immunosuppressive regimens (such as Azathioprine, Rituximab, Mycophenolate Mofetil, Methotrexate, Prednisone, Cyclophosphamide, and Mitoxantrone, Cyclosporin A, Tocilizumab), Combination therapies dominate the current therapeutic market. Although, NMO is still an incurable disease but the goal of treating acute NMO events is to improve relapse symptoms and restore neurological functions; long-term immunosuppression aims to prevent further attacks and maintain disease remission. Detailed chapter for upcoming therapies like Inebilizumab (Viela Bio), Satralizumab (Chugai Pharmaceutical/ Roche), Soliris (Alexion Pharma), Ultomiris (Alexion) have also been covered in the report.

Neuromyelitis optica spectrum disorder Market Outlook

The Neuromyelitis optica spectrum disorder market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Neuromyelitis optica spectrum disorder in 7MM was found to be USD 236.4 million in 2017.

Neuromyelitis optica spectrum disorder Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Neuromyelitis optica spectrum disorder Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Neuromyelitis optica spectrum disorder Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Neuromyelitis optica spectrum disorder Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Neuromyelitis optica spectrum disorder market
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis optica spectrum disorder market
  • To understand the future market competition in the Neuromyelitis optica spectrum disorder market.

Table of Contents

1. KEY INSIGHTS

2. NEUROMYELITIS OPTICA SPECTRUM DISORDER: MARKET OVERVIEW AT A GLANCE

  • 2.1. TOTAL MARKET SHARE (%) DISTRIBUTION OF NEUROMYELITIS OPTICA SPECTRUM DISORDER IN 2017
  • 2.2. TOTAL MARKET SHARE (%) DISTRIBUTION OF NEUROMYELITIS OPTICA SPECTRUM DISORDER IN 2028

3. NEUROMYELITIS OPTICA SPECTRUM DISORDER: DISEASE BACKGROUND AND OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. SIGNS AND SYMPTOMS
  • 3.3. CLINICAL FEATURES OF NMO/NMOSD
  • 3.4. CLASSIFICATION
  • 3.5. PATHOGENESIS
  • 3.6. DIAGNOSIS
  • 3.7. INTERNATIONAL CONSENSUS DIAGNOSTIC CRITERIA FOR NEUROMYELITIS OPTICA SPECTRUM DISORDERS
  • 3.8. NEUROIMAGING AND NEUROPHYSIOLOGIC TESTING
    • 3.8.1. Considerations for AQP4-IgG serologic and other laboratory testing.
    • 3.8.2. Pediatric NMOSD criteria
    • 3.8.3. Monophasic NMOSD
    • 3.8.4. Systemic autoimmunity associated with NMOSD.
    • 3.8.5. Pathology
    • 3.8.6. Opticospinal MS

4. EPIDEMIOLOGY AND PATIENT POPULATION

  • 4.1. KEY FINDINGS

5. 7MM TOTAL PREVALENT PATIENT POPULATION OF NMO/NMOSD

6. COUNTRY WISE-EPIDEMIOLOGY OF NMO/NMOSD

  • 6.1. UNITED STATES
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Prevalent Population of NMO/NMOSD
    • 6.1.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.1.4. Total Diagnosed Population of NMO/NMOSD
    • 6.1.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.1.6. Clinical Characterization of NMO/NMOSD
    • 6.1.7. Events of NMO/NMOSD
  • 6.2. EU5 COUNTRIES
    • 6.2.1. Assumptions and Rationale
  • 6.3. GERMANY
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Prevalent Population of NMO/NMOSD
    • 6.3.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.3.4. Total Diagnosed Population of NMO/NMOSD
    • 6.3.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.3.6. Clinical Characterization of NMO/NMOSD
    • 6.3.7. Events of NMO/NMOSD
  • 6.4. FRANCE
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Prevalent Population of NMO/NMOSD
    • 6.4.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.4.4. Total Diagnosed Population of NMO/NMOSD
    • 6.4.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.4.6. Clinical Characterization of NMO/NMOSD
    • 6.4.7. Events of NMO/NMOSD
  • 6.5. ITALY
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Total Prevalent Population of NMO/NMOSD
    • 6.5.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.5.4. Total Diagnosed Population of NMO/NMOSD
    • 6.5.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.5.6. Clinical Characterization of NMO/NMOSD
    • 6.5.7. Events of NMO/NMOSD
  • 6.6. UNITED KINGDOM
    • 6.6.1. Assumptions and Rationale
    • 6.6.2. Total Prevalent Population of NMO/NMOSD
    • 6.6.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.6.4. Total Diagnosed Population of NMO/NMOSD
    • 6.6.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.6.6. Clinical Characterization of NMO/NMOSD
    • 6.6.7. Events of NMO/NMOSD
  • 6.7. SPAIN
    • 6.7.1. Assumptions and Rationale
    • 6.7.2. Total Prevalent Population of NMO/NMOSD
    • 6.7.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.7.4. Total Diagnosed Population of NMO/NMOSD
    • 6.7.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.7.6. Clinical Characterization of NMO/NMOSD
    • 6.7.7. Events of NMO/NMOSD
  • 6.8. JAPAN
    • 6.8.1. Assumptions and Rationale
    • 6.8.2. Total Prevalent Population of NMO/NMOSD
    • 6.8.3. Gender-Specific Prevalent Population of NMO/NMOSD
    • 6.8.4. Total Diagnosed Population of NMO/NMOSD
    • 6.8.5. NMO-IgG Diagnosed Cases of NMO/NMOSD
    • 6.8.6. Clinical Characterization of NMO/NMOSD
    • 6.8.7. Events of NMO/NMOSD

7. TREATMENT

  • 7.1. TREATMENT ALGORITHM
    • 7.1.1. Treatment of Acute Attacks
    • 7.1.2. Preventive Treatment of Relapse
  • 7.2. TREATMENT GUIDELINES COUNTRY WISE
    • 7.2.1. American College of Chest Physicians Task Force
    • 7.2.2. European Federation of Neurological Societies (EFNS)

8. UNMET NEEDS

9. KEY CROSS COMPETITORS

10. EMERGING DRUGS

  • 10.1. INEBILIZUMAB: VIELA BIO
    • 10.1.1. Drug Description
    • 10.1.2. Other Development Activities
    • 10.1.3. Clinical Development
    • 10.1.4. Safety and Efficacy
    • 10.1.5. Product Profile
  • 10.2. SATRALIZUMAB (SA237): CHUGAI PHARMACEUTICAL/ ROCHE
    • 10.2.1. Drug Description
    • 10.2.2. Other Development Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Safety and Efficacy
    • 10.2.5. Product Profile
  • 10.3. SOLIRIS: ALEXION PHARMA
    • 10.3.1. Drug Description
    • 10.3.2. Regulatory Milestones
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Product Profile
  • 10.4. ULTOMIRIS: ALEXION
    • 10.4.1. Drug Description
    • 10.4.2. Other Development Activities
    • 10.4.3. Product Profile

11. NEUROMYELITIS OPTICA: 7 MAJOR MARKET ANALYSIS

  • 11.1. KEY FINDINGS
  • 11.2. MARKET SIZE OF NMO/NMOSD IN 7MM

12. UNITED STATES MARKET OUTLOOK

  • 12.1. UNITED STATES MARKET SIZE
    • 12.1.1. Total Market size of NMO/NMOSD
    • 12.1.2. Market Size by Therapies for Acute Management of NMO
    • 12.1.3. Market Size by Therapies for Preventive Management of NMO
    • 12.1.4. Market Size by Emerging Therapies

13. EU-5 COUNTRIES: MARKET OUTLOOK

  • 13.1. GERMANY
    • 13.1.1. Total Market size of NMO/NMOSD
    • 13.1.2. Market Size by Therapies for Acute Management of NMO
    • 13.1.3. Market Size by Therapies for Preventive Management of NMO
    • 13.1.4. Market Size by Emerging Therapies
  • 13.2. FRANCE
    • 13.2.1. Total Market size of NMO/NMOSD
    • 13.2.2. Market Size by Therapies for Acute Management of NMO
    • 13.2.3. Market Size by Therapies for Preventive Management of NMO
    • 13.2.4. Market Size by Emerging Therapies
  • 13.3. ITALY
    • 13.3.1. Total Market size of NMO/NMOSD
    • 13.3.2. Market Size by Therapies for Acute Management of NMO
    • 13.3.3. Market Size by Therapies for Preventive Management of NMO
    • 13.3.4. Market Size by Emerging Therapies
  • 13.4. UNITED KINGDOM
    • 13.4.1. Total Market size of NMO/NMOSD
    • 13.4.2. Market Size by Therapies for Acute Management of NMO
    • 13.4.3. Market Size by Therapies for Preventive Management of NMO
    • 13.4.4. Market Size by Emerging Therapies
  • 13.5. SPAIN
    • 13.5.1. Total Market size of NMO/NMOSD
    • 13.5.2. Market Size by Therapies for Acute Management of NMO
    • 13.5.3. Market Size by Therapies for Preventive Management of NMO
    • 13.5.4. Market Size by Emerging Therapies

14. JAPAN: MARKET OUTLOOK

  • 14.1. JAPAN MARKET SIZE
    • 14.1.1. Total Market size of NMO/NMOSD
    • 14.1.2. Market Size by Therapies for Acute Management of NMO
    • 14.1.3. Market Size by Therapies for Preventive Management of NMO
    • 14.1.4. Market Size by Emerging Therapies

15. MARKET DRIVERS

16. MARKET BARRIERS

17. APPENDIX

  • 17.1. REPORT METHODOLOGY

18. DELVEINSIGHT CAPABILITIES

19. DISCLAIMER

20. ABOUT DELVEINSIGHT

Back to Top